Trial Gives New Guidance for Choosing Initial PsA Treatment Trial Gives New Guidance for Choosing Initial PsA Treatment

Adding the tumor necrosis factor inhibitor adalimumab to methotrexate because of a lack of efficacy or tolerability produced better results than escalating the methotrexate dose alone.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Rheumatology News Source Type: news